Search for content, post, videos

Positive results from Bavarian Nordic

Bavarian Nordic announces positive results from a Phase 3 pivotal study of its investigational, non-replicating smallpox vaccine, IMVAMUNE.

The study achieved both of its primary endpoints, demonstrating IMVAMUNE’s efficacy in comparison to ACAM2000, the current US licensed replicating smallpox vaccine.

Study details

In this randomized, open-label study of 440 volunteers, the peak neutralizing antibodies induced by IMVAMUNE were shown to be 2-fold higher than those stimulated by ACAM2000. This met the co-primary endpoint of non-inferiority and was even shown to be a statistically superior immune response. A historical measure of efficacy against smallpox in people vaccinated for the first time was the induction of a vaccine take (pustule, scab and scar) following the skin vaccination (scarification) with replicating smallpox vaccines like ACAM2000.

However, the prevention or attenuation of a take in subjects that are re-vaccinated was a historical measure that a subject had a protective immune response against smallpox. Importantly, this co-primary endpoint was also successful. Primary vaccination with IMVAMUNE resulted in a highly attenuated take (reduction in lesion size), and prevented the vaccine take in the majority of subjects re-vaccinated with ACAM2000.

Plans to file a Biological License Application

IMVAMUNE has been given to more than 7,800 subjects in 21 clinical studies, including two Phase 3 studies that have supported a favorable safety profile and efficacy in comparison to replicating smallpox vaccines according to Bavarin Nordic. The company plans to file a Biological License Application in the second half of 2018. If approved, the company would also be eligible to receive a Priority Review Voucher, which could be used to accelerate the review of a future BLA, and is also transferrable.

“The success of this study represents a hallmark achievement at Bavarian Nordic. These and earlier study results validate the promise of IMVAMUNE for the prevention of smallpox and support product registration with the U.S. FDA,” said Paul Chaplin, President & CEO of Bavarian Nordic. “This program has only been possible through the consistent and strong support of numerous U.S. Government agencies and demonstrates what can be achieved through a successful public-private partnership to protect the public from the deliberate release of the smallpox virus.”

The Phase 3 study enrolled 440 subjects at a U.S. military garrison in South Korea led by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in collaboration with the U.S. Defense Health Agency (DHA).

Photo of Paul Chaplin: Bavarian Nordic